Results 151 to 160 of about 41,193 (294)

Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors [PDF]

, 2000
Jörg E Spang, Sonia Bertrand, G. Westera, J. T. Patt, P. August Schubiger, Daniel Bertrand   +5 more
openalex   +1 more source

Establishing an Ion Pair Interaction in the Homomeric {rho}1 {gamma}-Aminobutyric Acid Type A Receptor That Contributes to the Gating Pathway [PDF]

, 2007
{gamma}-Aminobutyric acid type A (GABAA) receptors are members of the Cys-loop superfamily of ligand-gated ion channels. Upon agonist binding, the receptor undergoes a structural transition from the closed to the open state, but the mechanism of gating ...
Dougherty, Dennis A., Lester, Henry A., Wang, Jinti   +2 more
core  

Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages

The FEBS Journal, EarlyView.
Butyrate mitigates intestinal inflammation in IBD. It does so primarily by suppressing pro‐inflammatory cytokines and costimulatory molecules in activated monocytes and macrophages, concomitant with enhancing pathogen clearance. In human colonic organoids, butyrate promotes epithelial expression of key genes involved in barrier function and immune ...
Daniela Parada‐Venegas, Marjorie De la Fuente López, Karen Dubois‐Camacho, Glauben Landskron, Tjasso Blokzijl, Héctor Molina, María‐Celeste Casanova, Yingying Cui, Moting Liu, Antonio M. Da Costa De Pina, Daniela Simian, María‐Julieta González, Rinse K. Weersma, Rodrigo Quera, Gerard Dijkstra, Klaas Nico Faber, Marcela A. Hermoso   +16 more
wiley   +1 more source

Preclinical Pharmacology of ABT‐594: A Nicotinic Acetylcholine Receptor Agonist for the Treatment of Pain [PDF]

, 2000
Michael D. Meyer, David J. Anderson, Jeffrey E. Campbell, Sherry Carroll, Kennan C. Marsh, A. David Rodrigues, Michael Decker   +6 more
openalex   +1 more source

The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Few studies have assessed whether dynamic kidney function prior to sodium–glucose cotransporter‐2 inhibitor (SGLT2i) initiation influenced subsequent renal outcomes. Thus, the study aimed to investigate whether combining estimated glomerular filtration rate (eGFR) slope and urinary albumin/creatinine ratio (UACR) change prior
Yen‐Chen Chiu, Wanchana Singhan, Surarong Chinwong, Dujrudee Chinwong, Shang‐Jyh Hwang, Yaw‐Bin Huang   +5 more
wiley   +1 more source

Isoflurane Increases the Apparent Agonist Affinity of the Nicotinic Acetylcholine Receptor by Reducing the Microscopic Agonist Dissociation Constant [PDF]

, 2000
Douglas E. Raines, Vinu T. Zachariah
openalex   +1 more source

Chronic Nicotine Selectively Enhances α4β2* Nicotinic Acetylcholine Receptors in the Nigrostriatal Dopamine Pathway [PDF]

, 2009
These electrophysiological experiments, in slices and intact animals, study the effects of in vivo chronic exposure to nicotine on functional α4β2* nAChRs in the nigrostriatal dopaminergic (DA) pathway.
Cai, Haijiang, Lester, Henry A., McIntosh, J. Michael, McKinney, Sheri, Nashmi, Raad, Xiao, Cheng   +5 more
core  

The exposomal imprint on rosacea: More than skin deep

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Rosacea reflects systemic and environmental interactions, not just a skin disorder. Key factors include environmental triggers, genetic and microbiome influences, diagnostic gaps in skin of colour and social determinants. Advances in multi‐omics and exposome integration highlight pathways towards precision medicine, prevention and equitable, patient ...
Katerina Grafanaki, Daniella Bakoli Sgourou, Alexandros Maniatis, Efstathia Pasmatzi   +3 more
wiley   +1 more source

UB-165: A Novel Nicotinic Agonist with Subtype Selectivity Implicates the α4β2* Subtype in the Modulation of Dopamine Release from Rat Striatal Synaptosomes [PDF]

, 2000
Christopher G. V. Sharples, Sergio Kaiser, L. Soliakov, Michael J. Marks, Allan C. Collins, Mark Washburn, Emma Wright, James A. Spencer, T. Gallagher, Paul Whiteaker, Susan Wonnacott   +10 more
openalex   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes

Journal of the American Geriatrics Society, EarlyView.
Effect of glucagon‐like peptide‐1 receptor agonist therapy on cardiorenal outcomes in patients aged ≥ 80 years with Type 2 diabetes. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however ...
Jui‐Cheng Chen, Yu‐Wei Fang, Ya‐Fang Liu, Mon‐Ting Chen, Ming‐Hsien Tsai   +4 more
wiley   +1 more source